Syntaxin is an Abingdon, UK-based biotechnology company developing novel biopharmaceuticals to control cell secretion. Its core technology is the Targeted Secretion Inhibitor (TSI) platform, designed to enable the design and development of therapeutics for diseases where inappropriate cell secretion is a primary cause. The company intends to apply the TSI platform across indications driven by pathological secretion, with an internal lead program targeting acromegaly. The lead acromegaly program is being progressed toward clinical proof-of-concept studies. Syntaxin has also signed a strategic alliance with Allergan, Inc. to develop a neuronal TSI candidate for chronic pain. The recent Series C financing will fund continued development of the TSI platform and advancement of the lead acromegaly program into clinical studies. Syntaxin is a biopharmaceutical company developing novel biologic drugs that control cell secretion. Its technology generates novel proteins that target selected cells to potently and sustainably control aberrant secretion of hormones or signalling molecules that contribute to disease. The company's pipeline targets unmet clinical needs in pain, nervous, respiratory and metabolic disorders. The funds raised will be used to advance the biologics pipeline towards clinical proof of mechanism and to reinforce its technology position. Syntaxin recently moved its laboratories to The Quadrant, Abingdon, near Oxford, having been founded at the Health Protection Agency at Porton Down. The Health Protection Agency remains a shareholder.

Total raised

$62M

Funding rounds

2

Latest round

Series C

Latest activity

Nov 2010